What is Lyrineur?
Lyrineur (Lyrineur) is an anti-epileptic drug, also called an anticonvulsant. Lyrineur works by slowing down nerve impulses in the brain and affects chemicals that send pain signals across the nervous system.
Lyrineur is a prescription medicine used to treat pain caused by damaged nerves in people with diabetes (diabetic neuropathy). Lyrineur is also used to treat pain caused by damaged nerves (neuropathic pain) that follows healing of shingles (herpes zoster). This condition is called post-herpetic neuralgia.
.
It is not known if Lyrineur is effective when used for the treatment of fibromyalgia, or when taken with other seizure medicines for adults with partial onset seizures.
Lyrineur is supplied as extended-release tablets in the following strengths: 82.5 mg, 165 mg, and 330 mg.
Lyrineur indications
Neuropathic Pain: Lyrineur is indicated for the treatment of neuropathic pain in adults, including neuropathic pain associated with spinal cord injury.
Epilepsy: Lyrineur is indicated as adjunctive therapy in adults with partial seizures, with or without secondary generalization.
Generalized Anxiety Disorder: Lyrineur is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.
Fibromyalgia: Lyrineur is indicated for the management of fibromyalgia.
How should I use Lyrineur?
Use Lyrineur solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Lyrineur solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Lyrineur solution refilled.
- Take Lyrineur solution by mouth with or without food.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Taking Lyrineur solution at the same time each day will help you remember to take it.
- Take Lyrineur solution on a regular schedule to get the most benefit from it.
- If you miss a dose of Lyrineur solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Lyrineur solution.
Uses of Lyrineur in details
Use: Labeled Indications
Fibromyalgia (immediate release only): Management of fibromyalgia
Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release): Management of neuropathic pain associated with diabetic peripheral neuropathy
Neuropathic pain associated with spinal cord injury (immediate release only): Management of neuropathic pain associated with spinal cord injury
Postherpetic neuralgia (immediate release and extended release): Management of postherpetic neuralgia
Seizures, focal (partial) onset (immediate release only): Adjunctive therapy in patients ≥1 month of age with focal onset (partial-onset) seizures
Off Label Uses
Cough, chronic refractory
Data from a limited number of patients in a controlled trial suggest that Lyrineur in combination with speech pathology therapy may be beneficial for the treatment of refractory chronic cough.
Based on the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause, the Endocrine Society guideline on the treatment of symptoms of menopause, and the North American Menopause Society (NAMS) position statement on nonhormonal management of menopause-associated vasomotor symptoms, Lyrineur is an effective and recommended alternative for the management of vasomotor symptoms associated with menopause in patients with contraindications to hormonal therapy or who prefer not to use hormonal therapy.
Lyrineur description
Each capsule contains the following inactive ingredients: Mannitol, maize starch and talc.
Lyrineur is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23.
Lyrineur is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05 M phosphate buffer) at pH 7.4 is -1.35.
Lyrineur dosage
The dose range is 150 to 600 mg per day given in either two or three divided doses.
Epilepsy: Lyrineur treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.
Generalised Anxiety Disorder: The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.
Lyrineur treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week, the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.
Discontinuation of Lyrineur: In accordance with current clinical practice, if Lyrineur has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Patients with Renal Impairment: Lyrineur is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As Lyrineur clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CrCl), as indicated in Table 1 determined using the following formula.
Lyrineur is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the Lyrineur daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment.
Patients with Hepatic Impairment: No dose adjustment is required for patients with hepatic impairment.
Children: The safety and efficacy of Lyrineur Sandoz in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No data are available.
Elderly (over 65 years of age): Elderly patients may require a dose reduction of Lyrineur due to a decreased renal function.
Administration: Lyrineur Sandoz may be taken with or without food.
Lyrineur Sandoz is for oral use only.
Lyrineur interactions
See also:
What other drugs will affect Lyrineur?
Since Lyrineur is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro and is not bound to plasma proteins, it is unlikely to produce or be subject to pharmacokinetic interactions.
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between Lyrineur and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that the oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on Lyrineur clearance.
Co-administration of Lyrineur with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance. Lyrineur may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of Lyrineur co-administered with oxycodone, lorazepam or ethanol did not result in clinically important effects on respiration. In the post-marketing experience, there are reports of respiratory failure and coma in patients taking Lyrineur and other CNS depressant medications. Lyrineur appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers.
Lyrineur side effects
See also:
What are the possible side effects of Lyrineur?
The Lyrineur clinical program involved over 8900 patients who were exposed to Lyrineur, of whom over 5600 were in double-blind placebo-controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving Lyrineur and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from Lyrineur treatment groups were dizziness and somnolence.
In Table 2 all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.
Additional reactions reported from post-marketing experience are included in italics in Table 2.
After discontinuation of short-term and long-term treatment with Lyrineur withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.
Concerning discontinuation of long-term treatment of Lyrineur, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
Lyrineur contraindications
See also:
What is the most important information I should know about Lyrineur?
You may have thoughts about suicide while taking this medication. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, insomnia, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
If you are taking Lyrineur to prevent seizures, keep taking the medication even if you feel fine.
Do not stop using Lyrineur without first talking to your doctor, even if you feel fine. You may have increased seizures or withdrawal symptoms such as headache, sleep problems, nausea, and diarrhea. Ask your doctor how to avoid withdrawal symptoms when you stop using Lyrineur.
Do not change your dose of Lyrineur without your doctor's advice. Tell your doctor if the medication does not seem to work as well in treating your condition.
Wear a medical alert tag or carry an ID card stating that you take Lyrineur. Any medical care provider who treats you should know that you take seizure medication.
Active ingredient matches for Lyrineur:
Pregabalin in Egypt.
List of Lyrineur substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Lyrica 利痛抑 (Hongkong) | |
| Lyrica cap 75 mg 56's (Pfizer) | |
| Lyrolin (Egypt) | |
| Lyzalon (Australia) | |
| Mar-Pregabalin (Canada) | |
| Mar-pregabalin capsule 25 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 300 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 50 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 100 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 75 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 200 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 150 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Mar-pregabalin capsule 225 mg (Marcan Pharmaceuticals Inc (Canada)) | |
| Martesia (Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama) | |
| Martesia 150 (Uruguay) | |
| Martesia 300 (Uruguay) | |
| Maxgalin (India) | |
| Maxgalin Capsule/ Tablet / 50mg / 10 units (Sun Pharma) | $ 0.63 |
| 50 mg x 10's (Sun Pharma) | $ 0.63 |
| 75 mg x 10's (Sun Pharma) | $ 0.99 |
| Maxgalin 50mg CAP / 10 (Sun Pharma) | $ 0.63 |
| Maxgalin 75mg CAP / 10 (Sun Pharma) | $ 0.99 |
| Maxgalin 150mg CAP / 10 (Sun Pharma) | $ 1.83 |
| MAXGALIN 100 MG TABLET ER 1 strip / 10 tablet ers each (Sun Pharma) | $ 1.66 |
| MAXGALIN 150 MG CAPSULE 1 strip / 10 capsules each (Sun Pharma) | $ 2.41 |
| MAXGALIN 150 MG TABLET ER 1 strip / 10 tablet ers each (Sun Pharma) | $ 2.51 |
| MAXGALIN 50 MG CAPSULE 1 strip / 10 capsules each (Sun Pharma) | $ 0.94 |
| MAXGALIN 75 MG CAPSULE 1 strip / 10 capsules each (Sun Pharma) | $ 1.45 |
| MAXGALIN 75 MG TABLET ER 1 strip / 10 tablet ers each (Sun Pharma) | $ 1.47 |
| Maxgalin cap 150 mg 10's (Sun Pharma) | |
| Maxgalin cap 300 mg 10's (Sun Pharma) | |
| Maxgalin cap 75 mg 10's (Sun Pharma) | |
| MAXGALIN cap 50 mg x 10's (Sun Pharma) | $ 0.71 |
| MAXGALIN cap 75 mg x 10's (Sun Pharma) | $ 1.12 |
| MAXGALIN cap 150 mg x 10's (Sun Pharma) | $ 1.83 |
| Maxgalin 100mg Tablet ER (Sun Pharma) | $ 0.18 |
| Maxgalin 150mg Capsule (Sun Pharma) | $ 0.26 |
| Maxgalin 150mg Tablet ER (Sun Pharma) | $ 0.26 |
| Maxgalin 50mg Capsule (Sun Pharma) | $ 0.09 |
| Maxgalin 75mg Capsule (Sun Pharma) | $ 0.15 |
| Maxgalin 75mg Tablet ER (Sun Pharma) | $ 0.16 |
| MAXGALIN-ER (India) | |
| 75 mg x 10's (Sun) | $ 1.06 |
| 100 mg x 10's (Sun) | $ 1.35 |
| 150 mg x 10's (Sun) | $ 1.87 |
| 300 mg x 10's (Sun) | $ 3.19 |
| Maxgalin-ER 75mg ER-TAB / 10 (Sun) | $ 1.06 |
| Maxgalin-ER 100mg ER-TAB / 10 (Sun) | $ 1.35 |
| Maxgalin-ER 150mg ER-TAB / 10 (Sun) | $ 1.93 |
| Maxgalin-ER 300mg ER-TAB / 10 (Sun) | $ 3.19 |
| MAXGALIN-ER modified-release tab 75 mg x 10's (Sun) | $ 1.14 |
| MAXGALIN-ER modified-release tab 100 mg x 10's (Sun) | $ 1.35 |
| MAXGALIN-ER modified-release tab 150 mg x 10's (Sun) | $ 2.02 |
| MAXGALIN-ER modified-release tab 300 mg x 10's (Sun) | $ 3.19 |
| Maxgalin-ER 75mg ER-TAB / 10 (Sun) | $ 1.06 |
| Maxgalin-ER 100mg ER-TAB / 10 (Sun) | $ 1.35 |
| Maxgalin-ER 150mg ER-TAB / 10 (Sun) | $ 1.93 |
| Maxgalin-ER 300mg ER-TAB / 10 (Sun) | $ 3.19 |
| MAXNERVE PG | |
| MAXNERVE PG SOFT GELATIN CAPSULE 1 strip / 10 soft gelatin capsules each (Bharti Life Sciences) | $ 1.99 |
See 1515 substitutes for Lyrineur | |
References
- DailyMed. "PREGABALIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Pregabalin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Pregabalin". http://www.drugbank.ca/drugs/DB00230 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lyrineur are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lyrineur. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
